ID   LMeC
AC   CVCL_L361
DR   Wikidata; Q54902752
RX   PubMed=15585963;
RX   PubMed=24035468;
RX   PubMed=28283079;
RX   PubMed=30268330;
CC   Doubling time: 34.1 +- 5.61 hours (PubMed=15585963).
CC   Sequence variation: Mutation; VGNC; VGNC:38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
CC   Breed/subspecies: Beagle; VBO=VBO_0200131.
DI   NCIt; C185639; Canine oral melanoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Female
AG   9Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 19-12-24; Version: 16
//
RX   PubMed=15585963; DOI=10.1292/jvms.66.1437;
RA   Inoue K., Ohashi E., Kadosawa T., Hong S.-H., Matsunaga S.,
RA   Mochizuki M., Nishimura R., Sasaki N.;
RT   "Establishment and characterization of four canine melanoma cell
RT   lines.";
RL   J. Vet. Med. Sci. 66:1437-1440(2004).
//
RX   PubMed=24035468; DOI=10.1016/j.tvjl.2013.08.003;
RA   Ito K., Kobayashi M., Kuroki S., Sasaki Y., Iwata T., Mori K.,
RA   Kuroki T., Ozawa Y., Tetsuka M., Nakagawa T., Hiroi T., Yamamoto H.,
RA   Ono K., Washizu T., Bonkobara M.;
RT   "The proteasome inhibitor bortezomib inhibits the growth of canine
RT   malignant melanoma cells in vitro and in vivo.";
RL   Vet. J. 198:577-582(2013).
//
RX   PubMed=28283079; DOI=10.1016/j.tvjl.2017.02.001;
RA   Yoshitake R., Saeki K., Watanabe M., Nakaoka N., Ong S.M.,
RA   Hanafusa M., Choisunirachon N., Fujita N., Nishimura R., Nakagawa T.;
RT   "Molecular investigation of the direct anti-tumour effects of
RT   nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell
RT   lines.";
RL   Vet. J. 221:38-47(2017).
//
RX   PubMed=30268330; DOI=10.1016/j.tvjl.2018.09.001;
RA   Miyamoto R., Kurita S., Tani H., Ikeda T., Ishizaka M., Saima H.,
RA   Kobayashi M., Tamura K., Bonkobara M.;
RT   "Canine squamous cell carcinoma cell lines with high expression of
RT   survivin are sensitive to survivin inhibitor YM155.";
RL   Vet. J. 240:31-36(2018).
//